Evangelos Giamarellos-Bourboulis
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hidradenitis Suppurativa | 5 | 2021 | 309 | 2.12 | Why? |
| Receptors, Urokinase Plasminogen Activator | 4 | 2021 | 252 | 1.78 | Why? |
| Sepsis | 16 | 2021 | 3517 | 1.70 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 6 | 2021 | 1165 | 1.60 | Why? |
| Hydrogen Sulfide | 2 | 2021 | 86 | 1.59 | Why? |
| Adalimumab | 3 | 2021 | 389 | 1.20 | Why? |
| Gram-Negative Bacteria | 3 | 2019 | 473 | 1.02 | Why? |
| Clarithromycin | 3 | 2018 | 112 | 0.92 | Why? |
| Respiratory Insufficiency | 7 | 2021 | 7301 | 0.90 | Why? |
| Antimicrobial Cationic Peptides | 1 | 2021 | 159 | 0.78 | Why? |
| Pneumonia, Ventilator-Associated | 2 | 2018 | 861 | 0.76 | Why? |
| Biological Variation, Individual | 1 | 2018 | 66 | 0.74 | Why? |
| Boronic Acids | 1 | 2018 | 30 | 0.73 | Why? |
| Penicillanic Acid | 1 | 2018 | 58 | 0.71 | Why? |
| Interleukin-1alpha | 1 | 2017 | 42 | 0.71 | Why? |
| Thienamycins | 1 | 2018 | 72 | 0.71 | Why? |
| Pyelonephritis | 1 | 2018 | 66 | 0.68 | Why? |
| beta-Defensins | 1 | 2016 | 38 | 0.64 | Why? |
| Gram-Negative Bacterial Infections | 2 | 2019 | 398 | 0.63 | Why? |
| Gene Dosage | 1 | 2016 | 101 | 0.63 | Why? |
| Greece | 7 | 2021 | 2091 | 0.61 | Why? |
| Anti-Infective Agents | 2 | 2019 | 1766 | 0.60 | Why? |
| Monocytes | 4 | 2020 | 2978 | 0.59 | Why? |
| Carbapenems | 1 | 2018 | 343 | 0.58 | Why? |
| Colistin | 4 | 2018 | 217 | 0.58 | Why? |
| Multigene Family | 1 | 2016 | 377 | 0.57 | Why? |
| Anti-Bacterial Agents | 9 | 2019 | 10083 | 0.57 | Why? |
| Interleukin-6 | 9 | 2021 | 7522 | 0.57 | Why? |
| Vascular Endothelial Growth Factor A | 2 | 2018 | 604 | 0.56 | Why? |
| Anesthetics | 1 | 2018 | 196 | 0.55 | Why? |
| BCG Vaccine | 3 | 2020 | 1137 | 0.53 | Why? |
| Pseudomonas Infections | 1 | 2018 | 425 | 0.51 | Why? |
| Tumor Necrosis Factor-alpha | 8 | 2019 | 2483 | 0.51 | Why? |
| Anesthesia, General | 1 | 2018 | 470 | 0.50 | Why? |
| Pseudomonas aeruginosa | 1 | 2018 | 652 | 0.50 | Why? |
| Urinary Tract Infections | 1 | 2018 | 534 | 0.47 | Why? |
| Shock, Septic | 2 | 2019 | 1313 | 0.46 | Why? |
| Leukocytes | 2 | 2021 | 1046 | 0.46 | Why? |
| Anti-Inflammatory Agents | 3 | 2021 | 6153 | 0.45 | Why? |
| Lymphohistiocytosis, Hemophagocytic | 1 | 2020 | 800 | 0.45 | Why? |
| Pneumonia, Bacterial | 1 | 2018 | 843 | 0.43 | Why? |
| Leukocytes, Mononuclear | 3 | 2021 | 2115 | 0.38 | Why? |
| Double-Blind Method | 4 | 2021 | 5988 | 0.35 | Why? |
| Apoptosis | 1 | 2018 | 2335 | 0.34 | Why? |
| Bacteremia | 1 | 2018 | 1372 | 0.34 | Why? |
| Biosensing Techniques | 1 | 2020 | 2116 | 0.31 | Why? |
| Placebos | 2 | 2021 | 629 | 0.31 | Why? |
| Interleukin-10 | 4 | 2021 | 1409 | 0.31 | Why? |
| Cost-Benefit Analysis | 1 | 2016 | 2259 | 0.31 | Why? |
| Male | 43 | 2021 | 367725 | 0.27 | Why? |
| Middle Aged | 34 | 2021 | 270681 | 0.27 | Why? |
| Female | 40 | 2021 | 380317 | 0.26 | Why? |
| Aged | 30 | 2021 | 215776 | 0.25 | Why? |
| Interleukin-1beta | 2 | 2018 | 992 | 0.25 | Why? |
| Biomarkers | 10 | 2021 | 23361 | 0.24 | Why? |
| Lymphopenia | 4 | 2021 | 2669 | 0.23 | Why? |
| Foundations | 1 | 2021 | 88 | 0.22 | Why? |
| Humans | 58 | 2021 | 930598 | 0.21 | Why? |
| Pneumonia | 1 | 2021 | 5652 | 0.21 | Why? |
| HLA-DR Antigens | 2 | 2020 | 563 | 0.21 | Why? |
| Antigens, Differentiation, Myelomonocytic | 1 | 2021 | 198 | 0.20 | Why? |
| Phenotype | 4 | 2021 | 4037 | 0.20 | Why? |
| Euthyroid Sick Syndromes | 1 | 2021 | 150 | 0.20 | Why? |
| ROC Curve | 4 | 2020 | 6024 | 0.20 | Why? |
| Aged, 80 and over | 15 | 2021 | 88759 | 0.19 | Why? |
| Respiratory Tract Infections | 1 | 2020 | 6817 | 0.19 | Why? |
| Cytokines | 5 | 2021 | 15010 | 0.19 | Why? |
| Arteriovenous Fistula | 1 | 2018 | 23 | 0.19 | Why? |
| Intracranial Arteriovenous Malformations | 1 | 2018 | 71 | 0.19 | Why? |
| Odds Ratio | 4 | 2019 | 5861 | 0.19 | Why? |
| Injections, Subcutaneous | 1 | 2021 | 647 | 0.19 | Why? |
| Prognosis | 8 | 2021 | 32490 | 0.19 | Why? |
| APACHE | 2 | 2018 | 682 | 0.19 | Why? |
| Methyl Ethers | 1 | 2018 | 22 | 0.18 | Why? |
| Piperacillin | 1 | 2018 | 63 | 0.18 | Why? |
| Severity of Illness Index | 13 | 2021 | 48226 | 0.18 | Why? |
| Administration, Intravenous | 3 | 2018 | 1115 | 0.18 | Why? |
| Receptors, IgG | 2 | 2019 | 578 | 0.18 | Why? |
| Daptomycin | 1 | 2018 | 64 | 0.18 | Why? |
| Antibodies, Monoclonal | 1 | 2017 | 8041 | 0.18 | Why? |
| Up-Regulation | 3 | 2021 | 2249 | 0.18 | Why? |
| Macrophage Activation | 1 | 2020 | 315 | 0.17 | Why? |
| Immunoenzyme Techniques | 1 | 2020 | 448 | 0.17 | Why? |
| Pneumonia, Viral | 9 | 2021 | 243684 | 0.17 | Why? |
| Receptors, Interleukin-1 | 1 | 2018 | 161 | 0.17 | Why? |
| Intraabdominal Infections | 1 | 2018 | 90 | 0.17 | Why? |
| Anesthesia, Epidural | 1 | 2018 | 92 | 0.17 | Why? |
| Interferon-gamma | 2 | 2018 | 2711 | 0.17 | Why? |
| Dyspepsia | 1 | 2017 | 60 | 0.17 | Why? |
| Peroxidase | 1 | 2018 | 207 | 0.17 | Why? |
| Chromosomes, Human, Pair 8 | 1 | 2016 | 25 | 0.16 | Why? |
| Blood Proteins | 1 | 2021 | 551 | 0.16 | Why? |
| Statistics, Nonparametric | 2 | 2018 | 1008 | 0.16 | Why? |
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 334 | 0.16 | Why? |
| Adult | 22 | 2021 | 244371 | 0.16 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.16 | Why? |
| Predictive Value of Tests | 3 | 2021 | 9537 | 0.16 | Why? |
| Receptors, Cell Surface | 1 | 2021 | 586 | 0.16 | Why? |
| Angiopoietin-2 | 1 | 2017 | 125 | 0.16 | Why? |
| Intention to Treat Analysis | 1 | 2018 | 673 | 0.15 | Why? |
| Survivors | 3 | 2018 | 2619 | 0.15 | Why? |
| Prospective Studies | 9 | 2021 | 43301 | 0.15 | Why? |
| Confidentiality | 1 | 2021 | 581 | 0.15 | Why? |
| Fluoroquinolones | 1 | 2017 | 235 | 0.15 | Why? |
| Macrolides | 1 | 2019 | 369 | 0.15 | Why? |
| Propofol | 1 | 2018 | 172 | 0.15 | Why? |
| Osteomyelitis | 1 | 2017 | 131 | 0.15 | Why? |
| Off-Label Use | 1 | 2020 | 553 | 0.15 | Why? |
| Antigens, CD | 1 | 2021 | 984 | 0.15 | Why? |
| Interleukin-18 | 1 | 2017 | 328 | 0.15 | Why? |
| Acinetobacter Infections | 1 | 2018 | 273 | 0.15 | Why? |
| Immunity, Innate | 4 | 2021 | 6570 | 0.14 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.14 | Why? |
| Urine | 1 | 2018 | 469 | 0.14 | Why? |
| Acinetobacter baumannii | 1 | 2018 | 378 | 0.14 | Why? |
| Interleukin-8 | 2 | 2019 | 964 | 0.14 | Why? |
| Intestine, Small | 1 | 2017 | 336 | 0.14 | Why? |
| Complement Activation | 1 | 2021 | 949 | 0.13 | Why? |
| Datasets as Topic | 1 | 2021 | 1404 | 0.13 | Why? |
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 290 | 0.13 | Why? |
| Multiple Organ Failure | 2 | 2021 | 1724 | 0.13 | Why? |
| Standard of Care | 1 | 2021 | 1297 | 0.13 | Why? |
| Macrophage Activation Syndrome | 1 | 2017 | 342 | 0.13 | Why? |
| Killer Cells, Natural | 2 | 2021 | 2093 | 0.13 | Why? |
| Time Factors | 4 | 2020 | 31397 | 0.13 | Why? |
| Platelet Activation | 1 | 2017 | 660 | 0.13 | Why? |
| Neutrophils | 2 | 2021 | 5476 | 0.13 | Why? |
| Area Under Curve | 1 | 2020 | 2564 | 0.13 | Why? |
| Metabolic Syndrome | 1 | 2021 | 810 | 0.13 | Why? |
| Virus Diseases | 2 | 2021 | 3779 | 0.12 | Why? |
| Steroids | 1 | 2019 | 904 | 0.12 | Why? |
| Amyotrophic Lateral Sclerosis | 1 | 2018 | 398 | 0.12 | Why? |
| Microbial Sensitivity Tests | 2 | 2018 | 2886 | 0.12 | Why? |
| Immunity | 2 | 2021 | 2651 | 0.12 | Why? |
| Incidence | 4 | 2021 | 25622 | 0.12 | Why? |
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2017 | 581 | 0.12 | Why? |
| Lymphocyte Count | 2 | 2021 | 4758 | 0.12 | Why? |
| Early Diagnosis | 1 | 2020 | 2443 | 0.11 | Why? |
| Crohn Disease | 2 | 2019 | 959 | 0.11 | Why? |
| Treatment Failure | 1 | 2017 | 2106 | 0.11 | Why? |
| Coronavirus | 1 | 2021 | 18339 | 0.11 | Why? |
| Colitis, Ulcerative | 2 | 2019 | 1037 | 0.11 | Why? |
| Immunomodulation | 1 | 2020 | 1472 | 0.11 | Why? |
| Precision Medicine | 1 | 2021 | 1477 | 0.11 | Why? |
| Transcriptome | 2 | 2021 | 3466 | 0.11 | Why? |
| Congresses as Topic | 1 | 2020 | 1347 | 0.11 | Why? |
| Fever | 1 | 2008 | 7795 | 0.10 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 711 | 0.10 | Why? |
| Inflammation | 4 | 2021 | 13255 | 0.10 | Why? |
| Disease Models, Animal | 4 | 2021 | 10998 | 0.10 | Why? |
| Decision Support Techniques | 1 | 2017 | 903 | 0.10 | Why? |
| Gene Expression Profiling | 1 | 2021 | 3788 | 0.10 | Why? |
| Survival Analysis | 3 | 2019 | 7592 | 0.10 | Why? |
| Adaptive Immunity | 1 | 2021 | 2585 | 0.09 | Why? |
| Drug Administration Schedule | 1 | 2016 | 2324 | 0.09 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.09 | Why? |
| Clinical Laboratory Techniques | 3 | 2020 | 23402 | 0.09 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 2309 | 0.09 | Why? |
| Acute Kidney Injury | 2 | 2020 | 5762 | 0.09 | Why? |
| Leukocyte Common Antigens | 2 | 2019 | 101 | 0.09 | Why? |
| Case-Control Studies | 5 | 2021 | 17671 | 0.09 | Why? |
| Ferritins | 1 | 2017 | 2055 | 0.09 | Why? |
| Treatment Outcome | 6 | 2021 | 51732 | 0.09 | Why? |
| Drug Combinations | 1 | 2018 | 3852 | 0.09 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2019 | 3607 | 0.09 | Why? |
| Malondialdehyde | 1 | 2008 | 113 | 0.09 | Why? |
| Disease Susceptibility | 1 | 2021 | 4002 | 0.09 | Why? |
| Systemic Inflammatory Response Syndrome | 2 | 2018 | 6653 | 0.09 | Why? |
| Cluster Analysis | 1 | 2016 | 3001 | 0.09 | Why? |
| Organ Dysfunction Scores | 3 | 2019 | 1475 | 0.09 | Why? |
| Staphylococcal Infections | 1 | 2017 | 1099 | 0.09 | Why? |
| Blood Coagulation | 1 | 2021 | 2768 | 0.09 | Why? |
| Hydrocortisone | 1 | 2018 | 1790 | 0.08 | Why? |
| Skin | 2 | 2018 | 2096 | 0.08 | Why? |
| Netherlands | 3 | 2021 | 3533 | 0.08 | Why? |
| Clinical Decision-Making | 1 | 2021 | 3755 | 0.08 | Why? |
| Patient Admission | 2 | 2021 | 5250 | 0.08 | Why? |
| C-Reactive Protein | 2 | 2020 | 7972 | 0.08 | Why? |
| Critical Illness | 4 | 2018 | 17281 | 0.08 | Why? |
| Recombinant Proteins | 1 | 2017 | 3786 | 0.08 | Why? |
| Oxygen | 1 | 2020 | 3715 | 0.08 | Why? |
| Blood Platelets | 1 | 2017 | 1704 | 0.08 | Why? |
| Disease Progression | 3 | 2021 | 13580 | 0.07 | Why? |
| Logistic Models | 2 | 2018 | 9089 | 0.07 | Why? |
| Genetic Predisposition to Disease | 2 | 2019 | 4027 | 0.07 | Why? |
| Acute Disease | 1 | 2018 | 6029 | 0.07 | Why? |
| Mice | 3 | 2021 | 21357 | 0.07 | Why? |
| Machine Learning | 1 | 2021 | 4395 | 0.07 | Why? |
| Inflammatory Bowel Diseases | 2 | 2019 | 3209 | 0.07 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.07 | Why? |
| Europe | 1 | 2021 | 12702 | 0.07 | Why? |
| Genotype | 1 | 2016 | 4697 | 0.07 | Why? |
| Intensive Care Units | 3 | 2021 | 29594 | 0.07 | Why? |
| Gene Frequency | 2 | 2019 | 1210 | 0.06 | Why? |
| Algorithms | 1 | 2020 | 7346 | 0.06 | Why? |
| B-Lymphocytes | 1 | 2018 | 4418 | 0.06 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.06 | Why? |
| Venous Thromboembolism | 1 | 2021 | 4273 | 0.06 | Why? |
| Complement C3c | 1 | 2021 | 10 | 0.06 | Why? |
| Ultrasonography | 1 | 2017 | 4409 | 0.06 | Why? |
| Pandemics | 10 | 2021 | 389249 | 0.05 | Why? |
| Animals | 6 | 2021 | 78931 | 0.05 | Why? |
| Hematopoiesis | 1 | 2021 | 168 | 0.05 | Why? |
| Germany | 1 | 2016 | 9196 | 0.05 | Why? |
| Immunoglobulin M | 1 | 2018 | 9091 | 0.05 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.05 | Why? |
| Lewis X Antigen | 1 | 2019 | 14 | 0.05 | Why? |
| Risk Factors | 2 | 2020 | 71621 | 0.05 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2019 | 10649 | 0.05 | Why? |
| Sensitivity and Specificity | 1 | 2020 | 22971 | 0.05 | Why? |
| Thyrotropin | 1 | 2021 | 262 | 0.05 | Why? |
| Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2019 | 40 | 0.05 | Why? |
| Thyroid Hormones | 1 | 2021 | 213 | 0.05 | Why? |
| Anticoagulants | 1 | 2021 | 9563 | 0.05 | Why? |
| Imipenem | 1 | 2018 | 57 | 0.05 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.05 | Why? |
| Young Adult | 6 | 2020 | 93724 | 0.05 | Why? |
| Adrenalectomy | 1 | 2018 | 32 | 0.05 | Why? |
| Interleukin-12 | 1 | 2019 | 156 | 0.05 | Why? |
| Leukocyte Count | 2 | 2019 | 3178 | 0.05 | Why? |
| Principal Component Analysis | 1 | 2021 | 689 | 0.05 | Why? |
| Systems Biology | 1 | 2021 | 320 | 0.04 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.04 | Why? |
| Cancellous Bone | 1 | 2017 | 14 | 0.04 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.04 | Why? |
| Cortical Bone | 1 | 2017 | 7 | 0.04 | Why? |
| Primates | 1 | 2021 | 584 | 0.04 | Why? |
| Keratinocytes | 1 | 2018 | 119 | 0.04 | Why? |
| Histocytochemistry | 1 | 2017 | 88 | 0.04 | Why? |
| Antigen Presentation | 1 | 2021 | 524 | 0.04 | Why? |
| Endothelium | 1 | 2021 | 460 | 0.04 | Why? |
| Carbohydrate Metabolism | 1 | 2017 | 44 | 0.04 | Why? |
| Extracellular Matrix | 1 | 2018 | 189 | 0.04 | Why? |
| Gastrointestinal Motility | 1 | 2017 | 78 | 0.04 | Why? |
| Serum Amyloid A Protein | 1 | 2018 | 211 | 0.04 | Why? |
| Primary Cell Culture | 1 | 2018 | 501 | 0.04 | Why? |
| Fermentation | 1 | 2017 | 156 | 0.04 | Why? |
| Clinical Trials as Topic | 3 | 2021 | 7330 | 0.04 | Why? |
| Proteoglycans | 1 | 2017 | 130 | 0.04 | Why? |
| Permeability | 1 | 2017 | 238 | 0.04 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.04 | Why? |
| Practice Guidelines as Topic | 2 | 2018 | 15421 | 0.04 | Why? |
| Debridement | 1 | 2017 | 172 | 0.04 | Why? |
| Platelet Function Tests | 1 | 2017 | 231 | 0.04 | Why? |
| Leukemia | 1 | 2021 | 598 | 0.04 | Why? |
| Rats, Wistar | 1 | 2018 | 621 | 0.04 | Why? |
| Myeloid Cells | 1 | 2021 | 808 | 0.04 | Why? |
| Hepatocytes | 1 | 2018 | 549 | 0.04 | Why? |
| Drug Synergism | 1 | 2018 | 833 | 0.04 | Why? |
| Lipopolysaccharide Receptors | 1 | 2018 | 357 | 0.04 | Why? |
| Retrospective Studies | 4 | 2021 | 105322 | 0.04 | Why? |
| Ferrets | 1 | 2021 | 1201 | 0.04 | Why? |
| Embolization, Therapeutic | 1 | 2018 | 269 | 0.04 | Why? |
| Vaccination | 1 | 2020 | 19050 | 0.03 | Why? |
| Injections, Intramuscular | 1 | 2017 | 800 | 0.03 | Why? |
| Down-Regulation | 1 | 2021 | 1416 | 0.03 | Why? |
| Fibroblasts | 1 | 2018 | 839 | 0.03 | Why? |
| Drug Therapy, Combination | 2 | 2018 | 7268 | 0.03 | Why? |
| Haplotypes | 1 | 2017 | 853 | 0.03 | Why? |
| Patient Acuity | 1 | 2021 | 1755 | 0.03 | Why? |
| Rabbits | 1 | 2017 | 1171 | 0.03 | Why? |
| Enterobacteriaceae | 1 | 2017 | 395 | 0.03 | Why? |
| Cricetinae | 1 | 2021 | 3344 | 0.03 | Why? |
| RNA | 1 | 2021 | 1278 | 0.03 | Why? |
| Immune Tolerance | 1 | 2018 | 608 | 0.03 | Why? |
| Gastroenteritis | 1 | 2017 | 489 | 0.03 | Why? |
| Syndrome | 1 | 2017 | 1310 | 0.03 | Why? |
| beta-Lactamases | 1 | 2018 | 759 | 0.03 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 7868 | 0.03 | Why? |
| Neoplasm Proteins | 1 | 2017 | 501 | 0.03 | Why? |
| Alleles | 1 | 2017 | 1557 | 0.03 | Why? |
| Sequence Analysis, RNA | 1 | 2021 | 2290 | 0.03 | Why? |
| Dose-Response Relationship, Drug | 1 | 2021 | 3776 | 0.03 | Why? |
| Creatinine | 1 | 2017 | 1443 | 0.03 | Why? |
| Flow Cytometry | 1 | 2019 | 2393 | 0.03 | Why? |
| Inflammasomes | 1 | 2017 | 710 | 0.03 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2018 | 1115 | 0.03 | Why? |
| Escherichia coli | 1 | 2018 | 1547 | 0.03 | Why? |
| Rats | 1 | 2018 | 2764 | 0.03 | Why? |
| Bacterial Proteins | 1 | 2018 | 1318 | 0.02 | Why? |
| Biopsy | 1 | 2018 | 2811 | 0.02 | Why? |
| Software | 1 | 2021 | 2501 | 0.02 | Why? |
| Interferons | 1 | 2021 | 2885 | 0.02 | Why? |
| Immunologic Memory | 1 | 2020 | 3362 | 0.02 | Why? |
| Videoconferencing | 1 | 2020 | 2081 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2018 | 5542 | 0.02 | Why? |
| Renal Replacement Therapy | 1 | 2016 | 1530 | 0.02 | Why? |
| Adolescent | 1 | 2018 | 86841 | 0.02 | Why? |
| Thromboembolism | 1 | 2020 | 2101 | 0.02 | Why? |
| Viruses | 1 | 2021 | 2238 | 0.02 | Why? |
| Lung Diseases | 1 | 2021 | 2361 | 0.02 | Why? |
| Cells, Cultured | 1 | 2018 | 5835 | 0.02 | Why? |
| Immunotherapy | 1 | 2020 | 2421 | 0.02 | Why? |
| Symptom Assessment | 1 | 2020 | 4967 | 0.02 | Why? |
| Inflammation Mediators | 1 | 2017 | 2654 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2021 | 9893 | 0.02 | Why? |
| Tuberculosis | 1 | 2021 | 2895 | 0.02 | Why? |
| Pilot Projects | 1 | 2016 | 5182 | 0.02 | Why? |
| Inpatients | 1 | 2021 | 5161 | 0.02 | Why? |
| Immunization, Passive | 1 | 2020 | 10067 | 0.02 | Why? |
| Critical Care | 2 | 2018 | 14081 | 0.02 | Why? |
| Gastrointestinal Microbiome | 1 | 2017 | 1961 | 0.02 | Why? |
| Mortality | 1 | 2021 | 7132 | 0.02 | Why? |
| Bacterial Infections | 1 | 2017 | 2229 | 0.02 | Why? |
| Liver | 1 | 2018 | 4007 | 0.02 | Why? |
| Drug Repositioning | 1 | 2021 | 5683 | 0.01 | Why? |
| Signal Transduction | 1 | 2018 | 7207 | 0.01 | Why? |
| Virus Internalization | 1 | 2020 | 7921 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.01 | Why? |
| Mutation | 1 | 2021 | 12376 | 0.01 | Why? |
| Models, Biological | 1 | 2017 | 4907 | 0.01 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.01 | Why? |
| Virus Replication | 1 | 2020 | 14331 | 0.01 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2020 | 8843 | 0.01 | Why? |
| Antiviral Agents | 2 | 2021 | 41703 | 0.01 | Why? |
| Global Health | 1 | 2020 | 13911 | 0.01 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.01 | Why? |
| Hospital Mortality | 1 | 2018 | 22087 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2021 | 27595 | 0.01 | Why? |
| Lung | 1 | 2020 | 31049 | 0.01 | Why? |